Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T40097
(Former ID: TTDC00102)
|
|||||
Target Name |
Stress-activated protein kinase JNK1 (JNK1)
|
|||||
Synonyms |
Stress-activated protein kinase 1c; SAPK1c; PRKM8; Mitogen-activated protein kinase 8; MAPK 8; MAP kinase 8; JNK-46; C-Jun N-terminal kinase 1
|
|||||
Gene Name |
MAPK8
|
|||||
Target Type |
Clinical trial target
|
[1] | ||||
Disease | [+] 1 Target-related Diseases | + | ||||
1 | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | |||||
Function |
Extracellular stimuli such as proinflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signaling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK8/JNK1. In turn, MAPK8/JNK1 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN, JDP2 and ATF2 and thus regulates AP-1 transcriptional activity. Phosphorylates the replication licensing factor CDT1, inhibiting the interaction between CDT1 and the histone H4 acetylase HBO1 to replication origins. Loss of this interaction abrogates the acetylation required for replication initiation. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including p53/TP53 and Yes-associates protein YAP1. In T-cells, MAPK8 and MAPK9 are required for polarized differentiation of T-helper cells into Th1 cells. Contributes to the survival of erythroid cells by phosphorylating the antagonist of cell death BAD upon EPO stimulation. Mediates starvation-induced BCL2 phosphorylation, BCL2 dissociation from BECN1, and thus activation of autophagy. Phosphorylates STMN2 and hence regulates microtubule dynamics, controlling neurite elongation in cortical neurons. In the developing brain, through its cytoplasmic activity on STMN2, negatively regulates the rate of exit from multipolar stage and of radial migration from the ventricular zone. Phosphorylates several other substrates including heat shock factor protein 4 (HSF4), the deacetylase SIRT1, ELK1, or the E3 ligase ITCH. Phosphorylates the CLOCK-ARNTL/BMAL1 heterodimer and plays a role in the regulation of the circadian clock. Phosphorylates the heat shock transcription factor HSF1, suppressing HSF1-induced transcriptional activity. Phosphorylates POU5F1, which results in the inhibition of POU5F1's transcriptional activity and enhances its proteosomal degradation. Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death.
Click to Show/Hide
|
|||||
BioChemical Class |
Kinase
|
|||||
UniProt ID | ||||||
EC Number |
EC 2.7.11.24
|
|||||
Sequence |
MSRSKRDNNFYSVEIGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAILERNVAIKKLSRP
FQNQTHAKRAYRELVLMKCVNHKNIIGLLNVFTPQKSLEEFQDVYIVMELMDANLCQVIQ MELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSF MMTPYVVTRYYRAPEVILGMGYKENVDLWSVGCIMGEMVCHKILFPGRDYIDQWNKVIEQ LGTPCPEFMKKLQPTVRTYVENRPKYAGYSFEKLFPDVLFPADSEHNKLKASQARDLLSK MLVIDASKRISVDEALQHPYINVWYDPSEAEAPPPKIPDKQLDEREHTIEEWKELIYKEV MDLEERTKNGVIRGQPSPLGAAVINGSQHPSSSSSVNDVSSMSTDPTLASDTDSSLEAAA GPLGCCR Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | PDB | ||||
ADReCS ID | BADD_A05675 ; BADD_A06356 ; BADD_A08298 | |||||
HIT2.0 ID | T29MD1 |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
1 | NKP-1339 | Drug Info | Phase 1 | Solid tumour/cancer | [2] | |
Preclinical Drug(s) | [+] 1 Preclinical Drugs | + | ||||
1 | COR-D | Drug Info | Preclinical | T-cell leukaemia | [3] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Inhibitor | [+] 69 Inhibitor drugs | + | ||||
1 | NKP-1339 | Drug Info | [4] | |||
2 | 7-azaindole derivative 1 | Drug Info | [5] | |||
3 | 7-azaindole derivative 2 | Drug Info | [5] | |||
4 | 7-azaindole derivative 3 | Drug Info | [5] | |||
5 | 7-azaindole derivative 5 | Drug Info | [5] | |||
6 | PMID25991433-Compound-A1 | Drug Info | [5] | |||
7 | PMID25991433-Compound-A10 | Drug Info | [5] | |||
8 | PMID25991433-Compound-A11 | Drug Info | [5] | |||
9 | PMID25991433-Compound-A2 | Drug Info | [5] | |||
10 | PMID25991433-Compound-A3 | Drug Info | [5] | |||
11 | PMID25991433-Compound-A5 | Drug Info | [5] | |||
12 | PMID25991433-Compound-A6 | Drug Info | [5] | |||
13 | PMID25991433-Compound-A7 | Drug Info | [5] | |||
14 | PMID25991433-Compound-A8 | Drug Info | [5] | |||
15 | PMID25991433-Compound-A9 | Drug Info | [5] | |||
16 | PMID25991433-Compound-D1 | Drug Info | [5] | |||
17 | PMID25991433-Compound-D2 | Drug Info | [5] | |||
18 | PMID25991433-Compound-E1 | Drug Info | [5] | |||
19 | PMID25991433-Compound-E2 | Drug Info | [5] | |||
20 | PMID25991433-Compound-E3 | Drug Info | [5] | |||
21 | PMID25991433-Compound-E4 | Drug Info | [5] | |||
22 | PMID25991433-Compound-E5 | Drug Info | [5] | |||
23 | PMID25991433-Compound-Eb | Drug Info | [5] | |||
24 | PMID25991433-Compound-F2 | Drug Info | [5] | |||
25 | PMID25991433-Compound-G1 | Drug Info | [5] | |||
26 | PMID25991433-Compound-G2 | Drug Info | [5] | |||
27 | PMID25991433-Compound-G4 | Drug Info | [5] | |||
28 | PMID25991433-Compound-G5 | Drug Info | [5] | |||
29 | PMID25991433-Compound-H1 | Drug Info | [5] | |||
30 | PMID25991433-Compound-H2 | Drug Info | [5] | |||
31 | PMID25991433-Compound-H3 | Drug Info | [5] | |||
32 | PMID25991433-Compound-J2 | Drug Info | [5] | |||
33 | PMID25991433-Compound-J3 | Drug Info | [5] | |||
34 | PMID25991433-Compound-J5 | Drug Info | [5] | |||
35 | PMID25991433-Compound-K1 | Drug Info | [5] | |||
36 | PMID25991433-Compound-K2 | Drug Info | [5] | |||
37 | PMID25991433-Compound-L1 | Drug Info | [5] | |||
38 | PMID25991433-Compound-N1 | Drug Info | [5] | |||
39 | PMID25991433-Compound-N3 | Drug Info | [5] | |||
40 | PMID25991433-Compound-O3 | Drug Info | [5] | |||
41 | PMID25991433-Compound-P1 | Drug Info | [5] | |||
42 | PMID25991433-Compound-P4 | Drug Info | [5] | |||
43 | PMID25991433-Compound-P5 | Drug Info | [5] | |||
44 | PMID25991433-Compound-P6 | Drug Info | [5] | |||
45 | 2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One | Drug Info | [7] | |||
46 | 2-(2-(butylamino)pyrimidin-4-ylamino)benzoic acid | Drug Info | [8] | |||
47 | 2-(2-(pentyloxy)pyrimidin-4-ylamino)benzoic acid | Drug Info | [8] | |||
48 | 2-(2-(phenylamino)pyrimidin-4-ylamino)benzamide | Drug Info | [8] | |||
49 | 2-(2-butoxypyrimidin-4-ylamino)benzoic acid | Drug Info | [8] | |||
50 | 2-(2-phenoxypyrimidin-4-ylamino)benzoic acid | Drug Info | [8] | |||
51 | 2-(2-propoxypyrimidin-4-ylamino)benzoic acid | Drug Info | [8] | |||
52 | 2-(2-sec-butoxypyrimidin-4-ylamino)benzoic acid | Drug Info | [8] | |||
53 | 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole | Drug Info | [9] | |||
54 | Aminopyridine deriv. 2 | Drug Info | [10] | |||
55 | AS-601245 | Drug Info | [11] | |||
56 | Bisindolylmaleimide-I | Drug Info | [1] | |||
57 | CI-1040 | Drug Info | [1] | |||
58 | JNK-IN-8 | Drug Info | [12] | |||
59 | KN-62 | Drug Info | [1] | |||
60 | KT-5720 | Drug Info | [1] | |||
61 | N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide | Drug Info | [13] | |||
62 | N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide | Drug Info | [10] | |||
63 | N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide | Drug Info | [10] | |||
64 | N-(6-ethoxypyridin-2-yl)acetamide | Drug Info | [10] | |||
65 | NM-PP1 | Drug Info | [11] | |||
66 | Phylomers | Drug Info | [4] | |||
67 | RO-316233 | Drug Info | [1] | |||
68 | Ro31-8220 | Drug Info | [1] | |||
69 | STAUROSPORINONE | Drug Info | [1] | |||
Activator | [+] 1 Activator drugs | + | ||||
1 | COR-D | Drug Info | [6] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. | |||||
REF 2 | ClinicalTrials.gov (NCT01415297) Dose Escalation Study of NKP-1339 to Treat Advanced Solid Tumors. U.S. National Institutes of Health. | |||||
REF 3 | ClinicalTrials.gov (NCT04022863) Ovarium Cancer Detection by TEP's and ctDNA. U.S. National Institutes of Health. | |||||
REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496). | |||||
REF 5 | c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72. | |||||
REF 6 | Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26. | |||||
REF 7 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||||
REF 8 | Discovery of a new class of 4-anilinopyrimidines as potent c-Jun N-terminal kinase inhibitors: Synthesis and SAR studies. Bioorg Med Chem Lett. 2007 Feb 1;17(3):668-72. | |||||
REF 9 | Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47. | |||||
REF 10 | Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80. | |||||
REF 11 | The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. | |||||
REF 12 | Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54. | |||||
REF 13 | Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors. J Med Chem. 2006 Jul 27;49(15):4455-8. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.